Corixa


Also found in: Thesaurus, Wikipedia.
Related to Corixa: Corixidae
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.Corixa - type genus of the Corixidae: boat bugsCorixa - type genus of the Corixidae: boat bugs
arthropod genus - a genus of arthropods
boat bug, water boatman - carnivorous aquatic bug having paddle-like hind legs
References in periodicals archive ?
Waggener Edstrom Bioscience, a division of Waggener Edstrom Strategic Communications, today announced the addition of Corixa Corp.
Corixa Corporation (Nasdaq: CRXA), Seattle, a developer of immunotherapeutics, and Beaufour Ipsen Group, a European global pharmaceutical company, have signed a license, development and commercialization agreement for Corixa's AnergiX.
Corixa Corporation (Nasdaq: CRXA), a developer of immunotherapeutics, Seattle, has announced that the United States Patent and Trademark Office (USPTO) has issued the company patents covering certain of its discoveries potentially useful in the diagnosis and treatment of Babesia microti (B.
Corixa Corporation (Nasdaq: CRXA), Seattle, a developer of immunotherapeutics, has announced results for the first quarter ended March 31, 2001.
Corixa Corporation (Seattle, WA; 206-754-5720), a research-based biotechnology company, announced that the United States Patent and Trademark Office has issued the company three patents granting composition and method claims covering Corixa's proprietary vaccine adjuvant protein known as Leishmania elongation Initiation Factor, or LeIF.
SEATTLE -- Corixa Corporation (Nasdaq:CRXA) today announced that its stockholders have adopted the merger agreement pursuant to which Corixa will be merged with and into a wholly owned subsidiary of SmithKline Beecham Corporation (d/b/a/ GlaxoSmithKline) and Corixa stockholders will receive $4.
gt;TX CORIXA GET $1 MILLION MILESTONE PAYMENT FROM JAPAN TOBACCO >TX Corixa Corporation (Nasdaq: CRXA), Seattle, a developer of immunotherapeutics, has received a $1 million milestone payment as a result of its research collaboration and license agreement with the pharmaceutical division of Japan Tobacco Inc.
and Corixa Corporation (Nasdaq: CRXA) today announced an agreement to discover and develop fully human antibody therapeutics.
Corixa Corporation (Nasdaq:CRXA), Seattle, a research and development-based biotechnology company, has been awarded a $2.
Corixa Corporation (Seattle, WA; 206-754-5720), a research-based biotechnology company, announced that the United States Patent and Trademark Office has issued to the University of Washington (Seattle, WA) a patent, which is licensed exclusively worldwide to Corixa, for treating disease where Her-2/neu is associated with the malignancy.
SEATTLE -- Corixa Corporation (Nasdaq:CRXA) today announced preliminary results of its first clinical trial of CRX-675, a toll-like receptor 4 (TLR4) agonist, in subjects allergic to ragweed.
Nasdaq: MEDX), a biopharmaceutical company, and Corixa Corporation (Nasdaq: CRXA), a research and development-based biotechnology company, today announced a collaboration to discover and develop fully human monoclonal antibodies against selected targets from Corixa's library of proprietary autoimmune disease, cancer and infectious disease antigens.